Public Shared Medical Q&A
This directory keeps different languages in one shared archive so search engines can discover the mixed-language corpus together. The filter below is only for browsing convenience.
JAK Inhibitors Long-term Monitoring
What important long-term adverse reactions should be monitored with JAK inhibitors?
**JAK inhibitors require structured long-term monitoring for serious adverse events including major adverse cardiovascular events (MACE), malignancy, venous thromboembolism (VTE), serious infections (particularly herpes zoster), and metabolic disturbances.*...
Rivaroxaban and Chinese Medicine Interaction
A patient on rivaroxaban wants to add a traditional Chinese medicine containing Danshen and Sanqi. Does the anticoagulation plan need to be adjusted?
## Conclusion Yes, the anticoagulation plan requires adjustment. The addition of a traditional Chinese medicine containing both Danshen (Salvia miltiorrhiza) and Sanqi (Panax notoginseng) to rivaroxaban therapy presents a clinically significant increased bl...
Semaglutide Cardiovascular Data East Asian
What long-term cardiovascular benefit and safety data are available for semaglutide in East Asian populations?
## Semaglutide in East Asian Populations: Long-Term Cardiovascular Benefit and Safety ### Clinical Evidence & Efficacy **Cardiovascular Outcomes in East Asian Subgroups** The available evidence for semaglutide's cardiovascular effects in East Asian populati...
LMWH Bridging Antiplatelet Risk
LMWH bridging antiplatelet therapy harm mechanism thrombotic risk
## LMWH Bridging in Antiplatelet Therapy: Harm Mechanism and Thrombotic Risk ### Clinical Evidence & Efficacy The retrieved evidence consistently demonstrates that **LMWH bridging is associated with increased harm without thrombotic benefit** in most periop...
Dupilumab High-Dose Effects
What are the adverse effects of high-dose dupilumab?
## Adverse Effects of High-Dose Dupilumab Based on the retrieved evidence, there is **no specific safety data or dedicated analysis for "high-dose" dupilumab** across the available sources. The adverse event profiles described in the retrieved literature an...
Lumakras Dosing Guidelines
What is the recommended dosing for Lumakras in KRAS-mutant non-small cell lung cancer?
The recommended dosage of Lumakras (sotorasib) for KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) is **960 mg orally once daily** until disease progression or unacceptable toxicity [4]. **The following flowchart illustra...
HER2-positive Breast Cancer Neoadjuvant Regimens
What neoadjuvant regimens are available for HER2-positive, HR-negative breast cancer?
Based on the retrieved 2024 CSCO Breast Cancer guidelines, the standard neoadjuvant approach for HER2-positive breast cancer is centered on anti-HER2 targeted therapy combined with chemotherapy. The HR-negative status does not alter the core HER2-directed s...
Dapagliflozin in HFrEF Low eGFR
For HFrEF patients starting the “foundational four”, is dapagliflozin still recommended when eGFR is below 30 ml/min/1.73m²?
**Yes, dapagliflozin is recommended for HFrEF patients with an eGFR below 30 mL/min/1.73 m², provided it is not initiated below 25 mL/min/1.73 m², and continuation is supported even below 20 mL/min/1.73 m² based on recent label updates and clinical trial da...
Aspirin Clopidogrel LMWH Bridging
For a patient on long-term aspirin plus clopidogrel who is scheduled for laparoscopic cholecystectomy, is LMWH bridging recommended before surgery, or is no bridging preferred?
**Conclusion: For a patient on long-term aspirin plus clopidogrel undergoing laparoscopic cholecystectomy, LMWH bridging is not recommended and is contraindicated as a bridging strategy for antiplatelet therapy. The preferred approach is to continue aspirin...
Atorvastatin CK Elevation
After atorvastatin use, CK has risen to three times the upper limit of normal but the patient has no obvious myalgia. Should the statin be stopped immediately?
**No, immediate discontinuation is not routinely indicated for asymptomatic CK elevation at 3× ULN.** ## Clinical Decision Framework ### Risk Stratification - **Asymptomatic CK elevation** (no myalgia, weakness, or tenderness) at 3× ULN falls into the **low...